Blinatumomab as a bridge to trasplantation in refractory Philadelphia chromosome negative b-cell acute lymphoblastic leukemia: a case report

被引：0
|
作者：
Rodriguez-Ferreras, A. [1 ]
Zapico-Garcia, I [1 ]
机构：
[1] Hosp Univ Cent Asturias, Unidad Gest Clin Farm, Avda Roma S-N, Oviedo 33011, Spain
来源：
ANALES DEL SISTEMA SANITARIO DE NAVARRA | 2019年 / 42卷 / 01期
关键词：
Blinatumomab; Philadelphia chromosome negative; Stem cell transplantation; Minimal residual disease; Refractory acute lymphoblastic leukemia; PHASE-II;
D O I：
10.23938/ASSN.0392
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Blinatumomab is a first class bispecific T-cell engager that has been shown to achieve negative minimal residual disease in patients with relapsed or refractory pre-B acute lymphoblastic leukemia after conventional chemotherapy. Nevertheless, there is little evidence about its role as an off label enhancer of cytological remission prior to stem cell transplantation (SCT). We describe the case of a patient with an excellent performance status who was allowed to undergo alogenic SCT after a single blinatumomab cycle, as well as the management of adverse events and the observed results.
引用
收藏
页码：75 / 78
页数：4
相关论文
共 50 条
  • [21] When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
    Cassaday, Ryan D.
    CANCER, 2020, 126 (02) : 253 - 255
  • [22] Dicentric translocation (9;12) presenting as refractory Philadelphia chromosome-positive acute B-cell lymphoblastic leukemia
    Bargetzi, MJ
    Mühlematter, D
    Tichelli, A
    Jotterand, M
    Wernli, M
    CANCER GENETICS AND CYTOGENETICS, 1999, 113 (01) : 90 - 92
  • [23] Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
    Queudeville, Manon
    Stein, Anthony S.
    Locatelli, Franco
    Ebinger, Martin
    Handgretinger, Rupert
    Goekbuget, Nicola
    Gore, Lia
    Zeng, Yi
    Gokani, Priya
    Zugmaier, Gerhard
    Kantarjian, Hagop M.
    CANCER, 2023, 129 (09) : 1384 - 1393
  • [24] Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia
    Senapati, Jayastu
    Jabbour, Elias
    Short, Nicholas J.
    Jain, Nitin
    Haddad, Fadi G.
    Kadia, Tapan M.
    Sasaki, Koji
    Alvarado-Valero, Yesid
    Takahashi, Koichi
    Dinardo, Courtney D.
    Daver, Naval
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Jacob, Jovitta
    Garris, Rebecca
    Kantarjian, Hagop
    BLOOD, 2024, 144 : 1442 - 1443
  • [25] European Commission grants Approval Extension for Blincyto® (Blinatumomab) for adult patients with Philadelphia Chromosome negative B-cell Progenitor of acute lymphoblastic Leukemia with minimal Residual Disease
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (03) : 157 - 157
  • [26] BUDGET IMPACT ANALYSIS COMPARING BLINATUMOMAB IN THE TREATMENT OF ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) WITH FLAG-IDA AND HYPER CVAD
    Naranjo, M.
    Alva, M. E.
    Munoz, I
    VALUE IN HEALTH, 2017, 20 (09) : A549 - A549
  • [27] Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
    Lee, Kum Ja
    Chow, Vivian
    Weissman, Ashley
    Tulpule, Sunil
    Aldoss, Ibrahim
    Akhtari, Mojtaba
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1301 - 1310
  • [28] FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia
    Pulte, E. Dianne
    Vallejo, Jonathon
    Przepiorka, Donna
    Nie, Lei
    Farrell, Ann T.
    Goldberg, Kirsten B.
    McKee, Amy E.
    Pazdur, Richard
    ONCOLOGIST, 2018, 23 (11): : 1366 - 1371
  • [29] Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Anthony Stein
    Janet L. Franklin
    Victoria M. Chia
    Deborah Arrindell
    William Kormany
    Jacqueline Wright
    Mandy Parson
    Hamid R. Amouzadeh
    Jessica Choudhry
    Guiandre Joseph
    Drug Safety, 2019, 42 : 587 - 601
  • [30] Super-refractory status epilepticus during blinatumomab initiation for B-cell acute lymphoblastic leukemia
    Rao, Chethan K.
    Kamoroff, Samuel
    Zorrilla, Julian
    Joyce, Michael
    Galan, Fernando N.
    IMMUNOTHERAPY, 2023, : 1437 - 1442
12345